Navigation Links
Misonix Schedules Fourth Quarter and Fiscal Year 2009 Financial Results Conference Call; October 1, 2009 at 4:30 p.m. Eastern
Date:9/29/2009

FARMINGDALE, N.Y., Sept. 29 /PRNewswire-FirstCall/ -- Misonix, Inc. (Nasdaq: MSON), a developer of minimally invasive ultrasonic medical device technology, which in Europe is used for the ablation of tumors and worldwide for other acute health conditions, today announced plans to release fourth quarter and fiscal year ended June 30, 2009 financial results on Thursday afternoon, October 1, 2009. Michael A. McManus, President and Chief Executive Officer and Richard Zaremba, Senior VP and Chief Financial Officer, will host a conference call at 4:30 p.m. Eastern on Thursday,October 1, 2009 to discuss the Company's fourth quarter and fiscal 2009 financial results.

Shareholders and other interested parties may participate in the conference call by dialing (866) 515-2909 (domestic) or (617) 399-5123 (international) and entering access code 61977194, a few minutes before the start of the call. A simultaneous webcast will be available via Misonix's website at www.misonix.com. The call will be archived on the Company's website for at least 90 days.

A recording of the live-call will be available approximately 2 hours after the event through October 8, 2009. The dial-in number to listen to the recording is (888) 286 8010 or (617) 801 6888. The replay access code is 35358896.

About Misonix:

Misonix, Inc. (Nasdaq: MSON) designs, develops, manufactures and markets therapeutic ultrasonic medical devices and laboratory equipment. Misonix's therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of $3 billion annually; Misonix's proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company's Web site at www.misonix.com.

    Investor Relations Contact:
    Kevin M. McGrath
    Cameron Associates, Inc.
    212 245 4577
    Kevin@cameronassoc.com

SOURCE Misonix, Inc.


'/>"/>
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. MDS Patients on Five-Day Vidaza(R) Dosing Schedules Achieve Transfusion Independence Consistent with Seven-day Schedule
2. Wyeth Applauds Six Countries Across Europe, and the Middle East, That Recently Announced the Inclusion of the 7-Valent Pneumococcal Conjugate Vaccine (PCV7) in Their Immunization Schedules
3. Orexigen(R) Therapeutics Schedules July 20, 2009 Teleconference and Webcast Discussion of Contrave(R) Phase 3 Results
4. Orexigen(R) Therapeutics Schedules September 30, 2009 Teleconference and Webcast to Discuss Phase 2b Trial Results From Second Obesity Drug Candidate, Empatic(TM)
5. Neurocrine Biosciences Reports Fourth Quarter and Year-End 2007 Results
6. Sangamo BioSciences Reports 2007 Fourth Quarter and Year-End Financial Results
7. PLC Systems Reports Fourth Quarter 2007 Results
8. Memory Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Financial Results
9. Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights
10. GeoVax Labs, Inc. Reports Fourth Quarter and Year-End 2007 Financial Results
11. Novavax Reports Fourth Quarter and 2007 Year-End Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... 7, 2016  Palatin Technologies, Inc. ("Palatin") (NYSE ... a previously disclosed underwritten public offering of units ... as sole book-running manager, Roth Capital Partners acted ... as co-manager for the offering. "This ... net proceeds, allowing us to continue advancing bremelanotide ...
(Date:12/7/2016)... , Dec. 7, 2016 DelveInsight,s, ... report provides in depth insights on the ... the Janus Kinase 3 (JAK3) Inhibitors. The ... various stages of development including Discovery, Pre-clinical, ... and Preregistration. Report covers the product clinical ...
(Date:12/7/2016)... YORK , Dec. 7, 2016 ... report on pulmonary drugs studies the current as ... The stakeholders of this report include companies and ... various pulmonary/respiratory drugs and/or drug-device combinations as well ... This report comprises an elaborate executive summary along ...
Breaking Medicine Technology:
(Date:12/8/2016)... ... December 08, 2016 , ... Healthcare ... Act. Dr. Botelho advocates for the mass media launching of story movements to ... opportunities to share their unfortunate experiences; such a movement can generate the network ...
(Date:12/8/2016)... ... December 08, 2016 , ... Peter ... communities in and around the greater Phoenix metropolitan region, is announcing a charity ... The mission of the Homeless Youth Connection is to promote community awareness of ...
(Date:12/7/2016)... PA (PRWEB) , ... December 07, 2016 , ... ... with the announcement that it is one of the early adopters completing EU-U.S. Privacy ... Framework is designed to provide companies on both sides of the Atlantic with a ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... and deep lines by smoothing and tightening the skin of the face to ... to address facial aging with very little downtime, Silhouette Instalift is a novel, ...
(Date:12/7/2016)... Ca (PRWEB) , ... December 07, 2016 , ... It ... that funding is with useful, properly analyzed data. The team at Beckman Coulter has ... address the 'need for speed' and the need to operate in a GLP (Good ...
Breaking Medicine News(10 mins):